• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

    6/12/24 7:00:00 AM ET
    $ASPI
    $ATRA
    $CIA
    $CLNN
    Major Chemicals
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASPI alert in real time by email

    MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Sponsors:

    QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions

    (844) 485-8200

    [email protected]

    www.QuoteMedia.com

    ProCore Advisory - Unleashing the power of strategic investor relations for public and pre-IPO companies

    (832)-847-1327

    [email protected]

    www.procoreadvisory.com

    Day 2

    June 13, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    FBR, Ltd. (OTCQB:FBRKF) (ASX: FBR) 

    Keynote speaker: Michael John Pivac, CEO & Managing Director

    9:40 - 10:10

    Huize Holding Limited (NASDQQ: HUIZ)

    Keynote speaker: Mr. Ron Tam, Co CFO

    10:15 - 10:45

    Ascend Wellness Holdings Inc. (OTCQX:AAWH)

    Keynote speaker: Rebecca Koar, EVP of Investor Relations and Strategy

    10:50 – 11:20

    Targa Exploration Corp. (OTCQB:TRGEF) (CSE:TEX)

    Keynote speaker: Cameron Tymstra, President & CEO

      

    11:25 - 11:55

    Sucro Limited (TSXV:SUG) (OTCQB:SUGCF)

    Keynote speaker: Don Hill, Chairman

    12:00 – 12:30

    Patriot AG Corp.

    Keynote speaker: Eric Till, CEO / CFO, & Kyle Severson, COO

    12:35 – 1:05

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

    Keynote speaker: Jason Awe, Head of Corporate Communications & IR

    1:10 – 1:40

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

      

    1:45 - 2:15

    InMed Pharmaceuticals, Inc. (NASDAQ:INM)

    Keynote speaker: Eric Adams, CEO

    2:20 – 2:30

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    2:35 - 2:45

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Gerald W. Shields, Vice Chairman and CEO Jeff Conklin, CFO

    2:50 – 3:00

    Digital Brand Media & Marketing Group, Inc. (OTC:DBMM)

    Keynote speaker: Reggie James, COO, Sr. VP & Exec. Director

    3:05 – 3:15

    ATRenew Inc. (NYSE:RERE)

    Keynote speakers: Jessie Jin, Investor Relations Manager & Jeremy Ji, Director of Corporate Development & Investor Relations

    3:20 - 3:30

    Meihua International Medical Technologies Co. (NASDAQ:MHUA)

    Keynote speaker: Mr. Steven Wang, CEO

    3:35 – 3:45

    GTI Energy, Ltd. (OTC:GTRIF) (ASX: GTR)

    Keynote speaker: Bruce Lane, Executive Director, CEO

    Presenting Today, June 12, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    Perfect Corp. (NYSE:PERF)

    Keynote speaker: Louis Chen, EVP, CSO

    9:40 - 10:10

    Intellabridge Technology Corporation (OTCQB:KASHF) (CSE:KASH)

    Keynote speaker: John Eagleton, CEO

    10:15 - 10:45

    Pulsar Helium, Inc.'s (OTCQB:PSRHF) (TSXV:PLSR)

    Keynote speaker: Thomas Abraham-James President / CEO

    10:50 - 11:20

    Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

    Keynote speaker: Mr. Quang X. Pham, Chairman & CEO

    11:25 - 11:55

    LogicMark, Inc. (NASDAQ:LGMK)

    Keynote speaker: Ms. Chia-Lin Simmons, CEO

      

    12:00 - 12:30

    Unusual Machines, Inc. (NYSE:UMAC)

    Keynote speaker: Allan Evans, CEO

    12:35 - 1:05

    SeaStar Medical Holding Corporation (NASDAQ:ICU)

    Keynote speaker: Eric Schlorff, President / CEO, Director

    1:10 - 1:40

    Diakonos Oncology, Inc.

    Keynote speakers: Jay Hartenbach, COO, & Anthony Baldor, CFO & Head of Business Development

    1:45 - 2:15

    Longeveron, Inc. (NASDAQ:LGVN)

    Keynote speaker: Mohamed Wa'el Hashad, CEO & Director

    2:20 - 3:00

    Clene Inc., (NASDAQ:CLNN)

    Keynote speaker: Rob Etherington, President / CEO, & Morgan Grown, CFO

    Postponed to July

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, and Harry M. Lander, Ph.D. Senior Scientific Consultant

    3:20 - 3:30

    SenesTech, Inc. (NASDAQ:SNES)

    Keynote speaker: Joel L. Fruendt, President, CEO, & Director

    3:35 - 4:05

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $ASPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI
    $ATRA
    $CIA
    $CLNN

    CompanyDatePrice TargetRatingAnalyst
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Unusual Machines Inc.
    $UMAC
    8/19/2025$15.00Buy
    Needham
    Unusual Machines Inc.
    $UMAC
    12/18/2024$18.00Buy
    Maxim Group
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Perfect Corp.
    $PERF
    10/21/2024$5.00Outperform
    Noble Capital Markets
    ASP Isotopes Inc.
    $ASPI
    10/4/2024$4.50Buy
    Canaccord Genuity
    Cadrenal Therapeutics Inc.
    $CVKD
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on ASP Isotopes with a new price target

    Cantor Fitzgerald initiated coverage of ASP Isotopes with a rating of Overweight and set a new price target of $13.00

    12/4/25 8:40:44 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Needham initiated coverage on Unusual Machines with a new price target

    Needham initiated coverage of Unusual Machines with a rating of Buy and set a new price target of $15.00

    8/19/25 8:37:18 AM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

    The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated with lower mortality risk, supporting NfL reduction as a candidate surrogate endpoint for accelerated approvalNew exploratory findings demonstrate that in responders with IGFBP7 biomarker decline, CNM-Au8 30mg was strongly associated with 78% reduced mortality risk (HR 0.22, p=0.01) in the HEALEY ALS Platform Trial, consistent with emerging genetic evidence linking lower IGFBP7 to ALS reversals SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (alo

    1/12/26 8:30:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION

    SECAUCUS, N.J., Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Pierre Fabre Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) stating that the Agency is unable to approve the tabelecleucel Biologics License Application (BLA) in its present form. We are surprised and deeply disappointed by the FDA's decision, particularly given the urgent and life-threatening unmet medical need faced by patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of standard-of-c

    1/12/26 8:05:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    SEC Filings

    View All

    Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    1/13/26 4:36:05 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ASP Isotopes Inc. filed SEC Form 8-K: Leadership Update

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    1/12/26 5:00:31 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Unusual Machines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Unusual Machines, Inc. (0001956955) (Filer)

    1/12/26 4:07:27 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mosca Alison was granted 16,667 shares and disposed of 57,219 shares (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 6:46:50 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ugwumba Chidozie sold $256,235 worth of shares (44,975 units at $5.70) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/12/26 4:38:18 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Skyline Announces Change in Strategy, New Management and First Acquisition in Critical Minerals Space

    Hong Kong, Nov. 06, 2025 (GLOBE NEWSWIRE) --  -Appoints Paul Mann Executive Chairman to Lead New Strategic Direction for the Company  -Company makes first Acquisition in Critical Minerals Space Hong Kong, November 6, 2025 (GLOBE NEWSWIRE) – Skyline Builders Group Holding Limited (NASDAQ:SKBL), a Cayman Islands exempted company (the "Company"), today announced a number of strategic changes to the Company's leadership, strategy and corporate headquarters. Appointment of Paul Mann as Executive Chairman Effective January 1, 2026, Paul E. Mann will become Executive Chairman of the Company. Mr. Mann has a 25-year career as an investor and entrepreneur. He is currently the Founder and Executiv

    11/6/25 8:15:00 AM ET
    $ASPI
    $SKBL
    Major Chemicals
    Industrials
    Engineering & Construction
    Consumer Discretionary

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Financials

    Live finance-specific insights

    View All

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials